Skip to content
value.today
Cue Biopharma, Inc. logo

Cue Biopharma, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2014
Total raised
$26 M
2 rounds on record
Latest round
$16 M
Dec 2016
First round on record
Jun 2015
Today
Went public
See the company page

Cue Biopharma, Inc. is listed today as Cue Biopharma, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Cue Biopharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2026$50 MPrivate placement after listing$50 to $250 million

Cue Biopharma, Inc.: Private sale, Jul 2026

Investors in this round

4 investors had bought by the notice of Jul 22, 2026: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dominic Borie · Executive Officer
  • Michael Meluzio · Executive Officer
  • Shao-Lee Lin · Executive Officer, Director
  • Sumita Ray · Executive Officer
  • Daniel Camardo · Director
  • Pamela Garzone · Director
  • Pasha Sarraf · Director
  • Viola Meehan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sumita Ray, JD, Chief Legal & Compliance Officer. Source: SEC Form D, newest notice filed Jul 22, 2026. Read the notice at the SEC.

equity, optionsSEC
May 2026$30 MPrivate placement after listing$10 to $50 million

Cue Biopharma, Inc.: Private sale, May 2026

Investors in this round

118 investors had bought by the notice of May 14, 2026: 118 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them, other: Pre-funded warrants to purchase shares of Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,800,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Colin Sandercock · Executive Officer
  • Daniel Baker · Executive Officer
  • Shao-Lee Lin · Executive Officer, Director
  • Frank Morich · Director
  • Jill M. Broadfoot · Director
  • Pamela D. Garzone · Director
  • Pasha Sarraf · Director
  • Patrick Verheyen · Director
  • Peter Kiener · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Newbridge Securities Corporation (CRD 104065) · Boca Raton, FloridaSold in all US states

Signed by Sumita Ray, JD, Chief Legal & Compliance Officer. Source: SEC Form D, newest notice filed May 14, 2026. Read the notice at the SEC.

optionsSEC
Nov 2022$30 MPrivate placement after listing$10 to $50 million

Cue Biopharma, Inc.: Private sale, Nov 2022

Investors in this round

64 investors had bought by the notice of Nov 21, 2022: 64 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,800,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anish R. Suri · Executive Officer
  • Colin G. Sandercock · Executive Officer
  • Daniel R. Passeri · Executive Officer, Director
  • Ken R. Pienta · Executive Officer
  • Kerri-Ann R. Millar · Executive Officer
  • Patricia R. Nasshorn · Executive Officer
  • Aaron G. Fletcher · Director
  • Frank G. Morich · Director
  • Frederick G. Driscoll · Director
  • Peter A. Kiener · Director
  • Tamar G. Howson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Public Ventures, LLC (CRD 42677) · Dallas, TexasSold in all US states
  • Piper Sandler & Co. (CRD 665) · Minneapolis, MinnesotaSold in all US states

Signed by Kerri-Ann Millar, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 21, 2022. Read the notice at the SEC.

equity, optionsSEC
Dec 2016$16 MNo. 2$10 to $50 million

Cue Biopharma, Inc.: Raise no. 2, Dec 2016

Investors in this round

133 investors had bought by the notice of Dec 30, 2016: 133 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$1,320,745
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Passeri · Executive Officer, Director · Chief Executive Officer
  • Gary Schuman · Executive Officer · Chief Financial Officer
  • Rodolfo Chaparro · Executive Officer · Vice President, Head of Immunology
  • Ronald Seidel Iii · Executive Officer · Executive Vice President, Head of Research and Development
  • Amy Wang · Director
  • Anthony Digiandomenico · Director
  • Barry Simon · Director
  • Cameron Gray · Director
  • Christopher Marlett · Director
  • Peter Kiener · Director
  • Steven Mcknight · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MDB Capital Group, LLC (CRD 42677) · Dallas, TexasSold in AR, AZ, CA, CO, CT, FL, IL, IN, MA, MD, MI, MN, MO, NJ, NV, NY, SC, TN, TX, VA, WA, WI

Signed by Daniel Passeri, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 30, 2016. Read the notice at the SEC.

equitySEC
Jun 2015$10 MNo. 1$10 to $50 million

Cue Biopharma, Inc.: Raise no. 1, Jun 2015

Investors in this round

121 investors had bought by the notice of Jun 19, 2015: 121 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$1,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amy Wang · Executive Officer, Director · Secretary
  • Cameron Gray · Executive Officer, Director · Chief Executive Officer and President
  • Gary Schuman · Executive Officer, Director · Chief Financial Officer
  • Rodolfo Chaparro · Executive Officer · Vice President, Head of Immunology
  • Ronald Seidel III · Executive Officer · Executive Vice President, Head of Research and Development
  • Steven Almo · Executive Officer · Chairman of Scientific Advisory Board
  • Anthony DiGiandomenico · Director
  • Christopher Marlett · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MDB Capital Group, LLC (CRD 42677) · Santa Monica, CaliforniaSold in AR, AZ, CA, CO, CT, DE, FL, IL, IN, KY, MD, NJ, NY, PA, SC, TN, TX, VA, WA, WI

Remarks in the notice

  • On fees: “Placement Agent, MDB Capital Group, LLC, received cash fee equal to 10% of shares sold and warrant to purchase 10% of shares sold (370,370).”

Signed by Cameron Gray, President and CEO. Source: SEC Form D, newest notice filed Jun 19, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cue Biopharma, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2026).

    SEC Form D · Jul 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2026

That is all the official record says: Cue Biopharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Cue Biopharma, Inc. are on record.

Investors#

No investor of Cue Biopharma, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 133 investors.

Largest shareholders today

Institutions holding Cue Biopharma, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cue Biopharma, Inc.
NameRoleNamed in
Dominic BorieExecutive officerJul 2026
Michael MeluzioExecutive officerJul 2026
Shao-Lee LinExecutive officerJul 2026
Sumita RayExecutive officerJul 2026
Colin SandercockExecutive officerMay 2026
Daniel BakerExecutive officerMay 2026
Anish R. SuriExecutive officerNov 2022
Colin G. SandercockExecutive officerNov 2022
Daniel R. PasseriExecutive officerNov 2022
Ken R. PientaExecutive officerNov 2022
Kerri-Ann R. MillarExecutive officerNov 2022
Patricia R. NasshornExecutive officerNov 2022
Daniel PasseriChief Executive OfficerDec 2016
Gary SchumanChief Financial OfficerDec 2016
Rodolfo ChaparroVice President, Head of ImmunologyDec 2016
Ronald Seidel IiiExecutive Vice President, Head of Research and DevelopmentDec 2016
Amy WangSecretaryJun 2015
Cameron GrayChief Executive Officer and PresidentJun 2015
Ronald Seidel IIIExecutive Vice President, Head of Research and DevelopmentJun 2015
Steven AlmoChairman of Scientific Advisory BoardJun 2015
Daniel CamardoDirectorJul 2026
Pamela GarzoneDirectorJul 2026
Pasha SarrafDirectorJul 2026
Shao-Lee LinDirectorJul 2026
Viola MeehanDirectorJul 2026
Frank MorichDirectorMay 2026
Jill M. BroadfootDirectorMay 2026
Pamela D. GarzoneDirectorMay 2026
Patrick VerheyenDirectorMay 2026
Peter KienerDirectorMay 2026
Aaron G. FletcherDirectorNov 2022
Daniel R. PasseriDirectorNov 2022
Frank G. MorichDirectorNov 2022
Frederick G. DriscollDirectorNov 2022
Peter A. KienerDirectorNov 2022
Tamar G. HowsonDirectorNov 2022
Amy WangDirectorDec 2016
Anthony DigiandomenicoDirectorDec 2016
Barry SimonDirectorDec 2016
Cameron GrayDirectorDec 2016

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.